Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
November 24, 2015 at 11:17 AM EST
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it ...